A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.

Inclusion Criteria:

• Single ascending dose (SAD) part:

• Male aged 18-55 years (both inclusive) at screening

• Body mass index between 18.5 kilogram per meter square (kg/m^2) and 27.0 kg/m^2 (both inclusive) at screening

• Considered to be generally healthy based on the medical history, physicalexamination, and the results of vital signs, electrocardiogram and clinicallaboratory tests performed during the screening visit, as judged by the investigator

• Multiple ascending dose (MAD) part (MAD QD and MAD QW):

• Male aged 18-55 years (both inclusive) at screening

• Body mass index between 25.0 kg/m^2 and 39.9 kg/m^2 (both inclusive) at screening.Overweight should be due to excess adipose tissue, as judged by the investigator

• Considered eligible based on the medical history, physical examination, and theresults of vital signs, electrocardiogram and clinical laboratory tests performedduring the screening visit, as judged by the investigator

• Type 2 diabetes (T2D) part:

• Female of non-childbearing potential or male aged 18-64 years (both inclusive) atscreening

• Body mass index between 25.0 kg/m^2 and 39.9 kg/m^2 (both inclusive) at screening

• Diagnosed with type 2 diabetes mellitus greater than or equal to (≥) 180 days beforescreening

• Treatment naive to antidiabetic drugs or on a stable daily dose(s) of metformintherapy (any metformin formulation any dose) greater than or equal to (>=) 60 daysbefore screening

• Insulin naive. However, short-term insulin treatment for a maximum of 14 days beforescreening is allowed, as is prior insulin treatment for gestational diabetes

• HbA1c in the range of 6.5% (inclusive) and 9.5% (inclusive)

Exclusion Criteria:

• Single ascending dose (SAD) part:

• Any disorder, which in the investigator's opinion might jeopardise participant'ssafety or compliance with the protocol

• Glycosylated haemoglobin (HbA1c) greater than or equal to (≥) 6.5 % (48 millimolesper mole (mmol/mol)) at screening

• Use of prescription medicinal products or non-prescription drugs, except routinevitamins, occasional use of paracetamol, ibuprofen, acetylsalicylic acid, anddomperidon, or topical medication not reaching systemic circulation, within 14 daysbefore screening

• Any disorder, which in the investigator's opinion might jeopardise participant'ssafety or compliance with the protocol

• Presence or history of any clinically relevant respiratory, metabolic, renal,hepatic, cardiovascular, gastrointestinal, or endocrinological conditions

• HbA1c greater than or equal to (≥) 6.5 % (48 mmol/mol) at screening

• Use of prescription medicinal products or non-prescription drugs, except routinevitamins, occasional use of paracetamol, ibuprofen, acetylsalicylic acid, anddomperidon, or topical medication not reaching systemic circulation, within 14 daysbefore screening

• Multiple ascending dose (MAD) part (MAD QD and MAD QW):

• Any disorder, which in the investigator's opinion might jeopardise participant'ssafety or compliance with the protocol

• Presence or history of any clinically relevant respiratory, metabolic, renal,hepatic, cardiovascular, gastrointestinal, or endocrinological conditions

• HbA1c greater than or equal to (≥) 6.5 % (48 mmol/mol) at screening

• Use of prescription medicinal products or non-prescription drugs, except routinevitamins, occasional use of paracetamol, ibuprofen, acetylsalicylic acid, anddomperidon, or topical medication not reaching systemic circulation, within 14 daysbefore screening

• Type 2 diabetes (T2D) part:

• Any disorder, except for conditions associated with T2D, which in the investigator'sopinion might jeopardise participant's safety or compliance with the protocol

• Presence or history of any clinically relevant respiratory, metabolic, renal,hepatic, gastrointestinal, endocrinological conditions (except conditions associatedwith diabetes mellitus)

• Current treatment with systemically effective corticosteroids, monoamine oxidase (MAO) inhibitors, systemic non-selective beta-blockers, growth hormone, non-routinevitamins or herbal products

• Current treatment with selected oral medication with a narrow therapeutic window,such as warfarin, digoxin, tricyclic antidepressants, lithium, aminophylline,theophylline and anticonvulsants